IL13

(redirected from Interleukin 13)
Also found in: Encyclopedia, Wikipedia.

IL13

A gene on chromosome 5q31 that encodes interleukin-13, an immunoregulatory cytokine produced primarily by activated Th2 cells which is involved in B-cell maturation and differentiation. IL13 upregulates CD23 and MHC class II expression and promotes IgE isotype switching in B cells; it downregulates macrophage activity, inhibiting production of pro-inflammatory cytokines and chemokines.

Molecular pathology
IL-13 plays a central in the pathogenesis of allergen-induced asthma by IgE- and eosinophil-independent mechanisms.
References in periodicals archive ?
In the new study, Chawla s team determined that both interleukin 4 and interleukin 13 recruit macrophages to fat and that the production of molecules called catecholamines by the macrophages causes the browning of white fat.
Interleukin 13 appears to be a potential central mediator of fibrosis in a variety of models and is found upstream of TGF-[beta]1, a well-known mediator of pulmonary fibrosis.
Currently, Targepeutics' three pharmaceutical platforms are Genetically Engineered Interleukin 13 (IL- 13), Immunotherapy (applications in cancer and asthma), and Anti-tumor Progression (targeting growth and ability of solid tumors to create new blood vessels).
TNX-650 is a monoclonal antibody targeting Interleukin 13, an important growth factor for malignant lymphoma cells.
Uvidem is a Cell Drug containing dendritic cells which have been generated using IDM's patented technology in presence of Interleukin 13.
Combined with Targepeutics' other exclusively licensed issued patents and several pending applications, these additionally patents give Targepeutics broad rights to commercialize its Genetically Engineered Interleukin 13 (IL-13) platform.
6,296,843 for its mutated interleukin 13 (IL-13) technology platform for the treatment of malignant glioma, a brain tumor (17,500 people annually; $200 million annual market).
Elias' team also found that patients receiving DiaPep277 produced more interleukin 10 and interleukin 13, hormone-like cytokine proteins that inhibit inflammation.
Further, the Company has signed an exclusive worldwide licensing agreement with the NIH and FDA to develop and commercialize a novel protein, the fusion of interleukin 13 (IL-13) and a Pseudomonas exotoxin.
Further, the Company also announced in October that it had signed an exclusive worldwide licensing agreement with the NIH and FDA to develop and commercialize a novel protein, the fusion of interleukin 13 (IL-13) and a Pseudomonas exotoxin.
This is the fusion of receptor-binding ligand interleukin 13 (IL-13) with a derivative of Pseudomonas exotoxin (PE38QQR).